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Muscarinic  acetylcholine  receptors  (mAChRs)  are  a
group of neurotransmitter proteins belonging to the seven
transmembrane  superfamily  of  receptors.  Five  distinct
receptor genes (CHRM1-CHRM5) have been cloned, which
encode for five separate muscarinic receptor proteins (M1-
M5), each with specific pharmacological properties [1-3].
Numerous studies have detailed a wide distribution for these
receptors  throughout  the  central  and  peripheral  nervous
systems.  However,  there  are  tissue-specific  subtype
expression patterns [4-6]. Studies have shown mAChRs are
responsible  for  diverse  physiologic  responses  such  as
increased  salivation,  smooth  muscle  contraction,  memory,
and  cardiac  function  [7-10]  while  drugs  targeting  the
muscarinic receptors have been developed for the treatment
of pathological conditions such as Alzheimer disease, asthma,
disorders of intestinal motility, and cardiac dysfunction [2].
Within the eye, mAChR genes and proteins have been
identified in several tissues and play critical roles in ocular
responses [11,12]. The ciliary body and iris sphincter express
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all  five  receptor  subtypes  with  the  M3  subtype  being
predominant [13-15]. Parasympathetic stimulation of these
tissues result in accommodation, altered aqueous outflow, and
contraction of the iris sphincter muscle [16,17]. While corneal
muscarinic  receptors  have  been  shown  to  be  involved  in
regulating growth of the corneal epithelium and have been
proposed to control corneal wound healing [18], innervation
of  the  choroid  leads  to  blood  vessel  dilation,  principally
through  the  M3  and  possibly  M5  receptor  subtypes  [19].
Muscarinic  receptors  are  also  thought  to  be  involved  in
regulating  retinal  embryonic  and  postnatal  development
[20-23] as well as modulating the activity of directionally-
sensitive ganglion cells [24,25].
In addition to the functional effects of mAChRs described
above, these receptors may also be involved in the postnatal
control of ocular growth. Numerous studies across a range of
animal models of myopia development have demonstrated
that  the  non-selective  antagonist,  atropine,  is  effective  in
preventing  the  axial  elongation  that  leads  to  myopia
development [26-29]. Human clinical trials have also detailed
the effectiveness of daily atropine administration, reducing
the progression of myopia by approximately 60% at least in
the  first  year  of  treatment  [30,31].  Another  non-selective
muscarinic antagonist, oxyphenonium, has also been reported
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Purpose: Muscarinic receptors are known to regulate several important physiologic processes in the eye. Antagonists to
these receptors such as atropine and pirenzepine are effective at stopping the excessive ocular growth that results in myopia.
However,  their  site  of  action  is  unknown.  This  study  details  ocular  muscarinic  subtype  expression  within  a  well
documented model of eye growth and investigates their expression during early stages of myopia induction.
Methods: Total RNA was isolated from tree shrew corneal, iris/ciliary body, retinal, choroidal, and scleral tissue samples
and was reverse transcribed. Using tree shrew-specific primers to the five muscarinic acetylcholine receptor subtypes
(CHRM1-CHRM5), products were amplified using polymerase chain reaction (PCR) and their identity confirmed using
automated sequencing. The expression of the receptor proteins (M1-M5) were also explored in the retina, choroid, and
sclera using immunohistochemistry. Myopia was induced in the tree shrew for one or five days using monocular
deprivation of pattern vision, and the expression of the receptor subtypes was assessed in the retina, choroid, and sclera
using real-time PCR.
Results: All five muscarinic receptor subtypes were expressed in the iris/ciliary body, retina, choroid, and sclera while
gene products corresponding to CHRM1, CHRM3, CHRM4, and CHRM5 were present in the corneal samples. The gene
expression data were confirmed by immunohistochemistry with the M1-M5 proteins detected in the retina, choroid, and
sclera. After one or five days of myopia development, muscarinic receptor gene expression remained unaltered in the
retinal, choroidal, and scleral tissue samples.
Conclusions: This study provides a comprehensive profile of muscarinic receptor gene and protein expression in tree
shrew ocular tissues with all receptor subtypes found in tissues implicated in the control of eye growth. Despite the efficacy
of muscarinic antagonists at inhibiting myopia development, the genes of the muscarinic receptor subtypes are neither
regulated early in myopia (before measurable axial elongation) nor after significant structural change.to inhibit myopia development in chicks [32]. In an attempt
to  reduce  side  effects  and  provide  information  on  the
mechanism of action, more specific muscarinic antagonists
have  been  investigated  for  their  effectiveness  at  reducing
myopia. Investigations have revealed only the M1 selective
pirenzepine  and  M2/M4  selective  himbacine  inhibiting
myopia development [29,33,34].
Despite the effectiveness of muscarinic antagonists at
inhibiting myopia, their mechanism of action remains unclear.
While  studies  involving  selective  antagonists  suggest  an
involvement of the M1 and/or M4 receptor, the high drug
concentrations  required  to  prevent  myopia  may  suggest
involvement of a non-cholinergic receptor mechanism such
as  the  nicotinic  system  [33-35].  This  uncertainty  is
compounded by the limited information on the exact site of
action of these drugs. While experimental evidence suggests
ocular growth is regulated locally [36], implicating the retina,
choroid, and/or sclera, the role of the retinal acetylcholine
system in eye growth has been discounted by Fischer et al.
[37]
While  the  mAChR  subtype  expression  has  been
investigated in the cornea, iris, ciliary body, and retina using
pharmacological, protein, and molecular techniques [11,15,
18,22], there is relatively less information on choroidal and
scleral expression. This is particularly the case in mammalian
models of myopia development where the characterization of
expression may aid in elucidating their effect on eye growth.
While relatively recent evidence highlights the expression of
the  five  receptor  subtypes  in  the  sclera  [38],  radioligand
binding experiments report no change in muscarinic receptor
density after two and seven days of myopia induction in the
chick [39]. This is not supported by mRNA data reporting a
selective mAChR subtype regulation in the sclera at a later
stage in myopia development (after 21 days) in the guinea pig
[40]. Such data may highlight species specific differences in
the mAChR system or reflect a downstream regulation of the
receptors  due  to  increased  eye  size.  If  the  mAChRs  are
involved in the development of myopia as suggested by the
capacity of antagonists to inhibit axial elongation in humans,
a  characterization  of  the  temporal  nature  of  mAChR
expression  during  the  early  stages  of  myopia  is  required.
Furthermore, examination of the mAChRs in different models
of ocular growth may highlight species-specific differences.
The present study details the expression profile of the five
mAChR subtypes in tree shrew ocular tissues using reverse
transcription  polymerase  chain  reaction  (RT–PCR)  and
immunohistochemistry. The tree shrew is a well documented
model in the understanding of eye growth and has been shown
to exhibit numerous similarities to human [41]. As mAChRs
may  be  involved  in  the  control  of  eye  growth  and  the
regulation of these receptors during myopia development is
equivocal,  the  gene  expression  of  the  five  subtypes  was
assessed in the retina, choroid, and sclera at early time points
before and after measurable changes in axial length. Since
these ocular tissues are thought to be involved in the control
of eye growth, this study provides further insight into the role
of muscarinic receptors and their antagonists in the control of
myopia development.
METHODS
Experimental model and paradigm: Maternally reared tree
shrews (Tupaia belangeri) were used in this study since they
have  similar  ocular  structure  to  humans  and  are  a  well
documented mammalian model for myopia [41,42]. Animals
were used 15 days after natural eye opening, a time when they
are  particularly  susceptible  to  eye  growth  changes  [41].
Myopia was induced monocularly in two groups of animals
for one or five days, using a translucent occluder attached to
a head mounted goggle (n=6 for each group). A third group
of animals were age matched (20 days post eye opening, n=6)
and  served  as  a  non-visually  manipulated  (binocularly
normal) control group. Lighting was on a 14:10 h light:dark
cycle, illumination was approximately 250 lux at cage floor
level,  and  food  and  water  were  available  ad  libitum.
Retinoscopy  and  A-scan  ultrasonography  measures  were
taken  under  anesthesia  at  baseline  and  after  the  specific
treatment  durations  previously  described  [43].  All
experimental protocols conformed to the ARVO statement for
the Use of Animals in Ophthalmic and Vision Research.
Ocular tissue collection: Animals were deeply anesthetized
with a mixture of ketamine (90 mg/kg) and xylazine (10 mg/
kg),  ocular  measures  were  taken,  and  a  terminal  dose  of
sodium pentobarbital (120 mg/kg) was administered. The eyes
were enucleated and hemisected, and the iris/ciliary body
complex (iris/ciliary body) and a 5 mm central corneal button
were collected. The posterior eyecup was flat mounted, and a
surgical trephine was used to isolate a 7 mm section from
which the retina, choroid, and posterior sclera were isolated.
To prevent contamination of the sclera with neural tissue, the
optic  nerve  head  was  removed  while  the  neural  retina
contained minimal retinal pigment epithelium (<20% of total
epithelium) after dissection. The remaining epithelial cells
were removed from choroidal samples using filter paper. All
dissected tissue samples were immediately frozen in liquid
nitrogen and stored at −80 °C until use.
Scleral fibroblast cell culture: Total sclera was isolated and
placed  in  a  culture  vessel  (Nunc,  Roskilde,  Denmark)
containing  Dulbecco’s  modification  of  Eagle’s  medium
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10%
fetal calf serum (FCS), 25 mM HEPES, 100 U/ml penicillin
and 100 μg/ml streptomycin (JRH, Melbourne, Australia).
Cell  outgrowth  from  explants  was  observed  after
approximately  one  week,  and  confluence  was  generally
reached after 2.5 weeks.
RNA extraction and reverse transcription: Total RNA was
extracted  from  the  tissue  samples  using  the  phenol-
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465chloroform extraction method of Chomczynski et al. [44]. To
limit  genomic  contamination,  samples  were  treated  with
DNase 1 (Promega Corp., Madison WI) before undergoing a
second  phenol-chloroform  extraction.  Commercial  spin
columns (RNeasy; Qiagen, Valencia, CA) were used to isolate
total RNA from the scleral fibroblast samples according to the
manufacturer’s instructions. The concentration and purity of
total  RNA  was  assessed  using  an  ultraviolet  (UV)
spectrophotometer  (Shimadzu,  Kyoto,  Japan).  Samples
(0.5 μg) were reverse transcribed using a commercial reverse
transcriptase and 1 μM oligo dT15 primer (M-MLV; Promega
Corp.).
Muscarinic receptor subtype gene expression: Fragments of
the  five  mAChR  genes  were  amplified  using  PCR  and
incorporating tree shrew-specific primers (Table 1). These
primers were designed using partial tree shrew muscarinic
receptor  sequences  obtained  by  direct  sequencing  of
amplification  products  that  were  generated  using  human-
specific primers [45]. At least one of the oligonucleotides in
each  subtype  primer  pair  was  designed  to  the  variable
cytoplasmic  loop  3  in  the  respective  subtypes  [46].
Amplification (PCR Express; Hybaid, Ashford, UK) of the
muscarinic  receptor  products  was  achieved  using  a
commercial ‘hotstart’ polymerase (HotStarTaq master mix;
Qiagen, Valencia, CA) and 1 μM of the respective primers.
For the majority of samples, 1.5mM MgCl2 was used in the
reaction, but different concentrations were required for retinal
CHRM3  (2  mM),  corneal  CHRM1  (3  mM),  and  retinal
CHRM5  (3  mM)  amplifications  to  optimise  product
amplification. After an initial denaturation at 95 °C for 10 min,
the samples underwent 40 cycles of denaturation (95 °C, 30
s), annealing (55 °C, 30 s), and extension (72 °C, 1 min). This
was followed by a final extension step at 72 °C for 10 min.
Individual products were subsequently purified (Qiaquick;
Qiagen) and sequenced (CEQ 8000 Genetic Analysis System;
Beckman Coulter, Fullerton, CA) to confirm identity.
Muscarinic receptor immunohistochemistry: For detection of
a mAChR protein, flat mounted posterior eyecups from age-
matched (20 days post eye opening, n=4) binocularly normal
tree shrews were fixed in 4% paraformaldehyde in phosphate
buffer  (0.1  M,  pH  7.4)  at  room  temperature  for  30  min.
Samples were cryoprotected in ascending concentrations of
sucrose (10%, 20%, and 30% in phosphate buffer) each for 1
h and then incubated overnight in 30% sucrose. The tissue
sections containing retina, choroid, and sclera were embedded
(OCT  compound,  Tissue-Tek;  Sakura  Finetek,  Torrance,
CA), and 12 µm sections were cut at −20 °C (Leica CM3050
S;  Leica,  Heidelberg,  Germany).  Multiple  sections
incorporating the posterior pole were collected on poly-L-
lysine  coated  slides  (Menzel-Glazer,  Braunschweig,
Germany) and stored at −20 °C until use.
Commercial  immunofluorescent  assay  kits  (IFA
muscarinic receptor kits; Research & Diagnostic Antibodies,
Benicia,  CA)  were  used  according  to  the  manufacturer’s
instructions to detect muscarinic receptor protein expression
in the retina, choroid, and sclera. Controls were incubated with
primary antibodies that had been blocked with the appropriate
neutralizing  antigen  (Research  &  Diagnostic  Antibodies).
Sections were observed microscopically (Axioplan/Axiophot
2; Zeiss, Oberkochen, Germany) using a 450–490 nm filter.
Real-time  polymerase  chain  reaction:  To  quantify  gene
expression changes during myopia development, real-time
PCR (LightCycler; Roche, Mannheim, Germany) was used.
Total RNA (0.5 μg) was reverse transcribed as described
above, and amplifications were performed using a commercial
PCR mix incorporating SYBR green 1 (FastStart DNA Master
Mix; Roche). The protocol for each receptor subtype was
optimized  to  ensure  that  a  single,  specific  product  was
produced (Table 1). The melting temperatures for CHRM1 (92
°C), CHRM2 (86 °C), CHRM3 (88 °C), CHRM4 (92 °C), and
CHRM5 (91 °C) PCR products were empirically determined.
Changes in gene expression were assessed with reference to
the  housekeeping  gene,  hypoxanthine  phosphoribosyl
TABLE 1. MUSCARINIC RECEPTOR SUBTYPE OLIGONUCLEOTIDE PRIMERS AND OPTIMIZED REAL-TIME PCR CONDITIONS.
Receptor                                              Oligonucleotide primers (5′-3′)
Real-time PCR conditions
subtype Forward Reverse
Size
(bp)
MgCl2
(mM)
Ann
temp
(°C)
Det
temp
(°C)
CHRM1 GGAAGAGGAGAGGGATGAAGG TTCGGGAACACAGTCCTTG 365 2 63 89
CHRM2 TCATGACTGCGCTCTATTGG GGGCTTTTCCATTGTGGAT 197 3 60 82
CHRM3 GCCATCTTGTTCTGGCAATAC AGCGGCCATACTTCCTCC 325 2 60 82
CHRM4 ACACCGTGTACATCGTCAAG CAGGAGATGTGGATGTAGAGC 394 2 60 86
CHRM5 CCAACTCACAGGGCTTTTCT GTGAGCTGCTCGGCTTTG 173 3 60 87
Tree shrew-specific primers were designed for the five mAChR subtypes and were used to detect mRNA expression in the cornea,
iris/ciliary body, retina, choroid, sclera, and scleral fibroblasts. The optimized conditions used to assess gene expression changes
during myopia development are also included. Under “Real-time PCR conditions”, “Ann temp” stands for annealing temperature
and “Det temp” stands for signal detection temperature.
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466transferase  (HPRT),  as  described  previously  [47].  Group
mean  data  were  expressed  as  the  percentage  difference
between treated and control eyes (±SEM) for the myopia-
induced group or left and right eyes (±SEM) for the normal
group. Data were analyzed using GraphPad Prism software
(GraphPad Software Inc., La Jolla, CA).
RESULTS
Expression of mAChR mRNA in tree shrew ocular tissues was
examined using RT–PCR. Figure 1 shows the amplification
products for CHRM1 (365 bp), CHRM2 (197 bp), CHRM3
(325 bp), CHRM4 (394 bp), and CHRM5 (173 bp) receptor
genes  in  the  different  tissues  investigated.  The  iris/ciliary
body, retina, choroid, and sclera expressed all five muscarinic
receptor subtypes while CHRM2 expression was not detected
in the cornea. Amplified products for all the receptor subtypes
were also detected in samples isolated from cultured tree
shrew scleral fibroblasts. An additional band in some of the
CHRM4 amplifications was due to primer-dimer formation as
assessed by real-time PCR melt curves while there were no
other  contaminating  products.  For  each  mAChR  subtype,
amplifications were performed using the respective total RNA
tissue sample as a template. Therefore, the amplifications
were controlled for genomic contamination. No products were
observed in any of these control amplifications. Purification
and sequencing of the respective muscarinic receptor products
showed  a  high  identity  to  the  published  human  receptor
sequences  (CHRM1  93%,  CHRM2  83%,  CHRM3  89%,
CHRM4 93%, and CHRM5 82%).
Localization  of  the  M1-M5  mAChR  proteins  was
investigated in the retina, choroid, and sclera using specific
monoclonal  antibodies  directed  against  the  respective
receptor  subtypes.  The  distribution  and  stratification  of
muscarinic receptors in the tree shrew retina are shown in
Figure 2 (first column) together with the respective bright-
field sections and negative controls (middle and last columns,
respectively).
Relatively selective retinal expression was observed for
the M1, M2, and M3 receptors. M1 immunoreactivity was
localized to the outer (OPL) and inner (IPL) plexiform layers
while the somata of cells in the inner nuclear layer (INL) and
ganglion cell layer (GCL) exhibited limited staining. The M2
receptor  was  localized  to  the  outer  segments  of  the
photoreceptor  layer,  OPL,  IPL,  and  the  nerve  fiber  layer
(NFL) while the M3 receptor exhibited a quite distinctive
expression in the OPL and NFL with processes extending
through the INL and terminating at the IPL, which may be
consistent with Müller cell expression. The specificity of the
detection  is  evidenced  by  the  blocking  of  the
immunoreactivity after the addition of synthetic neutralizing
peptides to the M1, M2, and M3 receptors (Figure 2, last
column).
More diffuse retinal immunoreactivity was observed for
the M4 and M5 receptors with stronger staining observed in
the outer segments of photoreceptors and the OPL for M4
while M5 staining was strongest in the outer segments of
photoreceptors and around the somata of cells in the INL and
GCL.  Again,  the  addition  of  the  respective  neutralizing
peptides blocked all immunoreactivity.
Figure 1. Muscarinic receptor subtype
gene expression in the tree shrew eye.
RT–PCR  and  tree  shrew-specific
primers were used to amplify mAChR
subtypes  in  tree  shrew  corneal,  iris/
ciliary  body,  retinal,  choroidal,  and
scleral  tissue  samples  as  well  as  in
cultured  scleral  fibroblasts.  Products
corresponding  to  the  muscarinic
receptor  subtypes,  CHRM1  (365  bp),
CHRM2  (197  bp),  CHRM3  (325  bp),
CHRM4  (394  bp),  and  CHRM5  (173
bp),  were  amplified  in  most  tissue
cDNA  samples  (+)  while  the
corresponding total RNA was used to
control for genomic contamination (-).
Nucleic acid size markers in base pairs
are indicated.
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Statistics:  The  retinoscopy  and  A-scan  ocular  data  were
assessed  using  t-tests  and  one-way  analysis  of  variance
(ANOVA)  for  within  and  between  treatment  groups,
respectively. For the gene expression data, t-tests were used
to assess treated–control differences within each group while
the normal, 1 day and 5 day groups were compared using one
way ANOVA.Figure  2.  Retinal  muscarinic  receptor
subtype protein expression in the tree
shrew. Tree shrew posterior eye cups
were fixed in 4% paraformaldehyde and
reacted  with  muscarinic  monoclonal
antibodies to their respective receptor
subtypes.  A  FITC-labeled  secondary
antibody  was  used  to  visualize  the
protein distribution in the retina (first
column).  The  corresponding  bright-
field  section  (second  column)  and
negative controls (last column) are also
shown.  The  layers  of  the  retina  are
highlighted, and the scale bar represents
20 μm. ONL, outer nuclear layer; OPL,
outer  plexiform  layer;  INL,  inner
nuclear  layer;  IPL,  inner  plexiform
layer; GCL, ganglion cell layer; NFL,
nerve fiber layer.
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468Figure 3 shows the distribution of the muscarinic receptor
subtypes in the choroid and sclera. All receptors (M1-M5)
showed staining in the choroid and sclera with scleral staining
appearing between the collagen fiber bundles. All staining
was blocked by the addition of the respective neutralizing
peptides (Figure 3, last column).
As muscarinic receptor antagonists are able to inhibit
myopia development both in animal models [28,29,33,34] and
in humans [30,31] and there is conflicting data regarding the
regulation of these receptors during myopia, real-time PCR
was  used  to  determine  whether  muscarinic  receptor  gene
expression was altered in the tree shrew during experimental
myopia. Each of the receptor subtypes was assessed at two
time periods during myopia development, one representing a
time before significant structural change (1 day) and the other
after measurable ocular elongation (5 days). These time points
were chosen to assess whether the mAChRs were actively
involved in the early stages in myopic eye growth. Biometric
data for the 5 day occluded group and age-matched normal
group is shown in Table 2. In the 5 day occluded group,
relative myopia had developed during the treatment period
(treated eye–control eye, −8.1±0.6 D, p<0.0001). Most of the
corresponding  increase  in  eye  size  (treated–control  eye,
0.20±0.2 mm, p<0.001) could be attributed to an increase in
vitreous  chamber  depth  (treated  eye–control  eye,
0.17±0.01 mm, p<0.0001) with anterior chamber depth and
lens  thickness  not  significantly  altered  (data  not  shown;
p=0.46 and p=0.25, respectively). There was no difference
between the normal age-matched animals and the control eyes
from the 5 day occluded group.
Muscarinic  gene  expression  was  assessed  in  retinal,
choroidal,  and  scleral  tissues,  each  of  which  has  been
proposed as a potential site for atropine and/or pirenzepine
action in halting myopia progression [48]. As observed in
Figure 4, retinal muscarinic gene expression was not altered
for any of the subtypes during the development of myopia
(either  1  or  5  days)  when  treated  (occluded)  eyes  were
compared to their contralateral control (open) eyes. Data from
the  binocularly  normal  (visually  unmanipulated)  animals
showed no difference in gene expression between left and
right eyes. The choroidal (Figure 5) and scleral (Figure 6)
tissue samples also showed no alteration in mAChR subtype
gene expression during myopia development.
DISCUSSION
This study investigated mAChR gene and protein expression
in the ocular tissues of the tree shrew and detailed subunit gene
expression  during  the  development  of  myopia.  All  five
mAChR subtypes were found in the tree shrew iris/ciliary
body, retina, choroid, and sclera while CHRM2 mRNA was
not detected in the cornea. mAChR subtype mRNA expression
was not altered early in myopia development in the retina,
choroid,  or  sclera  either  before  or  after  significant  axial
elongation. Despite these tissues being implicated in the eye
growth  control,  mAChRs  do  not  play  a  direct  role  in  the
development of myopia in the tree shrew.
The tree shrew choroid and sclera contained the mRNA
and protein for all five mAChR subtypes. Pharmacological
and immunohistochemical localization techniques have been
previously  used  to  identify  M1–M4  in  the  choroid  [19,
49-51]. However, this appears to be the first report of the M5
subtype.  The  scleral  gene  data  reflects  previous  reports
highlighting the expression of all mAChR subtype mRNA in
the  guinea  pig  and  human  sclera  [38,40,52].
Immunohistochemical staining showed mAChR protein to be
distributed evenly throughout the sclera. As there is limited
innervation of the sclera and the labeling occurs between the
collagen  fiber  bundles,  it  is  likely  that  the  mAChRs  are
localized  to  the  scleral  fibroblast  processes.  This  was
confirmed by the amplification of all five subtypes in cultured
scleral fibroblasts. Similar receptor expression was found in
human sclera and scleral fibroblast cells [38]. Chick scleral
chondrocytes have also been suggested to express mAChRs
due to their regulation via muscarinic antagonists [53]. The
non-neuronal  origin  of  scleral  mAChR  expression  is  not
unusual, with other non-neural ocular tissues, such as the lens
expressing mAChR subtypes [52]. Despite the constituents of
the cholinergic system being present in several other cell
systems, which are non-neuronal in origin [54], its functional
role remains unclear.
The tree shrew iris/ciliary body complex also expressed
all five mAChRs, which is in agreement with reports showing
mRNA  [14,15]  and  protein  [14]  expression  for  all  five
receptors in the human iris/ciliary body. Similarly, the mRNA
and protein for all five mAChR subtypes was demonstrated in
the tree shrew retina/RPE complex. This is consistent with
reports that the mRNA for all five receptors has been found
in  the  human  retina  [52].  Several  other  reports  have  also
demonstrated the expression of individual subtypes such as
M1, M2, M3, and M4 in retinae from various animals [13,
23,55,56]. The distribution of the M1-M3 receptors in the
plexiform layers of the retina is in agreement with previous
localization of these subtypes [50,56,57]. However, while M4
expression in the photoreceptors, INL, and GCL is similar to
that reported for chick retina [50], the receptor expression was
generally more diffuse in the tree shrew. These observations
may represent specific differences in the distribution of retinal
mAChRs  between  the  tree  shrew  and  the  chick  or
alternatively, differences in antibody specificities. To the best
of our knowledge, this appears to be the first report showing
M5 protein expression across the retina. While the current data
shows its distribution to be similar to the M4 receptor, the lack
of specific M5 antagonists at present makes its retinal role
unclear. However, expression of M5 in the fish RPE may be
involved in pigment granule dispersion [58].
The CHRM1, CHRM3, CHRM4, and CHRM5 subtypes
were identified in the cornea, which is supported by Lind and
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469Figure  3.  Choroidal  and  scleral
muscarinic  receptor  subtype  protein
expression in the tree shrew. Tree shrew
posterior  eye  cups  were  fixed  in  4%
paraformaldehyde  and  reacted  with
muscarinic  monoclonal  antibodies  to
the  respective  receptor  subtypes.  A
FITC-labeled secondary antibody was
used to visualize the protein distribution
in the choroid (CH) and sclera (SC; first
column).  The  corresponding  bright-
field  section  (second  column)  and
negative controls (last column) are also
shown.  The  choroid  (CH)  and  sclera
(SC)  are  labeled,  and  the  scale  bar
represents 20 μm.
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470Cavanagh, [18] who detailed the expression of mAChR-like
proteins of comparable molecular weights to the M3, M4, M5,
and either the M2 or M1 receptors in cultured rabbit corneal
cells. The CHRM2 subtype mRNA was not detected in the
current  study  depite  the  use  of  multiple  amplification
conditions. This subtype has been reported in bovine epithelial
cells by Socci et al. [59,60] using the same technique and
recently in human corneal epithelium and endothelium using
immunohistochemistry. While this discrepancy may reflect
species differences, it is difficult to prove that a protein is not
expressed in a particular tissue. This is evidenced by the fact
that the CHRM1,CHRM3, and CHRM4 transcripts were not
detected in the Socci et al. [59,60] study and the M1 and M3
receptors were not found in the human cornea.
Despite the presence of all receptor subtypes in the tree
shrew  retina,  choroid,  and  sclera,  mAChR  subtype  gene
expression was not altered after 1 (before significant structural
change)  or  5  (after  significant  ocular  elongation)  days  of
myopia development. This is somewhat surprising if mAChR
signaling is directly involved in eye growth since these tissues
have been implicated in the local control of eye growth and
the stimulation of mAChRs is known to alter subtype gene
expression  [36,61].  However,  these  data  are  generally
consistent with previous work investigating the cholinergic
system  during  myopia  development.  Within  the  retina,
receptor density [27,39,62], levels of acetylcholine [63], and
the activity of choline acetyltransferase [64] have all been
reported  to  remain  unchanged  during  the  development  of
myopia. Likewise, studies on choroidal receptor density and
affinity  have  shown  no  myopia-induced  difference  [39]
despite earlier evidence of altered choline acetyltransferase
activity in the choroid of form-deprived chicks [64].
Muscarinic  receptors  have  long  been  implicated  in
myopia development due to the inhibitory effects of mAChR
antagonists such as atropine, pirenzepine, and himbacine [26,
29,34]. Yet, while the efficacy of these drugs is not a result of
ocular toxicity [65], the mechanism remains unclear. Based
on  the  retinal  data  showing  unchanged  receptor  density/
activity,  the  high  doses  required  to  inhibit  experimental
myopia, and the inability of quisqualic acid treatment to affect
atropine-induced prevention of myopia [37], an extra-retinal
site has been proposed. The current gene expression data
supports a non-retinal site of action for these drugs. However,
it provides no evidence for choroidal and/or scleral mAChR
involvement  during  myopia  development.  While  the
investigation  of  choroidal  and  scleral  mAChR  protein
expression would be required to discount post-translational
TABLE 2. OCULAR MEASURES FOR NORMAL TREE SHREWS AND THOSE UNDERGOING FIVE DAYS OF MONOCULAR DEPRIVATION.
Ocular measures
Normal group                                                          Myopic group
Normal eyes Control eyes Treated eyes Treated-control eyes
Refraction (D) 8.6±0.1 8.4±0.1 0.3±0.5 -8.1±0.6**
Vitreous chamber depth (mm) 2.79±0.01 2.82±0.02 2.98±0.02 0.17±0.01**
Axial length (mm) 7.12±0.02 7.09±0.04 7.29±0.06 0.20±0.02*
Tree shrew ocular measures were taken before the isolation of the tissue samples. Refraction, vitreous chamber depth, and axial
length  are shown for the normal (visually unmanipulated) animals and the 5 day monocular deprived (myopic) group. Data are
shown as mean±SEM, n=6. The asterisk indicates p<0.001, and the double asterisk indicates p<0.0001.
Figure  4.  Regulation  of  retinal
muscarinic  receptor  subtype  gene
expression during myopia development.
The regulation of the five mAChRs was
assessed in the tree shrew retina using
real-time  PCR  and  the  DNA-binding
dye, SYBR green I. Data was calculated
relative  to  the  housekeeping  gene,
HPRT,  and  expressed  relative  to  the
contralateral  control  eye  (for  myopic
groups)  or  left/right  eyes  (for  normal
groups). Data are shown as the mean
percentage change±SEM (n=6).
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471alterations during myopia, an indirect role for mAChRs in eye
growth appears more likely.
One such indirect effect of muscarinic antagonists on eye
growth was proposed by Schwahn et al. [66]. In their study,
an  in  vitro  application  of  atropine  induced  a  spreading
depression in the retinal ERG response while the inhibition of
myopia in vivo was accompanied by an increase in dopamine
release. Such data lead to the hypothesis that atropine may
interrupt  the  ocular  growth  signal  via  excessive  retinal
dopamine  release.  Whether  such  an  effect  would  be  via
receptoral or non-receptoral mechanisms is unclear. However,
the  capacity  of  antagonists  to  utilize  non-muscarinic
mechanisms has been previously reported [67].
becoming  a  more  commonly  used  model  in  eye  growth
studies, there are limited data describing the scleral response
(structural  and  biochemical)  during  myopia  development.
Therefore,  it  is  difficult  to  compare  the  two  models.  An
important consideration in comparing the two studies is that
Liu et al. [40] induced myopia over a 21 day period rather than
the 1 and 5 day period used in the current study. Thus, the
observed alterations in M1 and M4 receptor expressions may
reflect later changes arising from the enlarged eye rather than
reflecting a causal relationship with eye growth. With respect
to methodological issues, the guinea pig gene expression data
was estimated from ethidium bromide band intensity using
non-competitive end point PCR. Quantitative assessment of
mRNA expression requires the measurement of the log-linear
phase of the PCR amplification curve since the linear phase
(end point) of the amplification curve can be affected by
technical  limitations  such  as  primer-dimer  formation  and
Figure  5.  Regulation  of  choroidal
muscarinic  receptor  subtype  gene
expression during myopia development.
The regulation of the five mAChRs was
assessed in the tree shrew choroid using
real-time  PCR  and  the  DNA-binding
dye, SYBR green I. Data was calculated
relative  to  the  housekeeping  gene,
HPRT,  and  expressed  relative  to  the
contralateral  control  eye  (for  myopic
groups)  or  left/right  eyes  (for  normal
groups). Data are shown as the mean
percentage change±SEM (n=5 for 1 and
5 day CHRM2 gene data, all other data
n=6).
Figure  6.  Regulation  of  scleral
muscarinic  receptor  subtype  gene
expression during myopia development.
The regulation of the five mAChRs was
assessed in the tree shrew sclera using
real-time  PCR  and  the  DNA-binding
dye, SYBR green I. Data was calculated
relative  to  the  housekeeping  gene,
HPRT,  and  expressed  relative  to  the
contralateral  control  eye  (for  myopic
groups)  or  left/right  eyes  (for  normal
groups). Data are shown as the mean
percentage change±SEM (n=5 for 5 day
myopia data, 1 day myopia and normal
data, n=6).
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The current study directly contradicts the data of Lui et
al. [40] where M1- and M4-specific increases in mAChR gene
and protein expression were observed in the guinea pig during
myopia development. This discrepancy may reflect species
differences or methodological issues. While the guinea pig isreduced reagent concentrations. Therefore, the linear phase
provides limited quantitative information [68].
An earlier report of M1 and M4 regulation in the retina,
choroid, and sclera after pirenzepine inhibition of myopia
development in the guinea pig [69] could also be interpreted
as demonstrating a direct muscarinic eye growth mechanism.
Such an interpretation could be supported by data showing
pirenzepine,  being  M1  selective,  and  himbacine  (M4
selective) specifically inhibit experimentally induced myopia.
However, an addition of muscarinic antagonists is known to
result in increased receptor expression [61], and it is unclear
from the report whether the pirenzepine-induced increase in
the M1 and M4 receptors directly reduced the myopia or was
merely a result of it. Nevertheless, while there appears to be
limited if any change in the ligands or receptors within the
acetylcholine  system  in  most  animal  models  of  myopia
development, it is possible that alterations in downstream
muscarinic signaling may directly modulate eye growth. For
example,  mAChR  internalization,  desensitization,  and
downregulation  of  signal  transduction  elements  can  also
function to modulate receptor-mediated function [61]. Further
work will be required to investigate these possibilities.
Tree shrew retina, choroid, and sclera express all five
mAChR  subtypes,  but  there  is  no  alteration  in  tissue
expression levels during myopia development. The lack of
any regulatory change in the gene expression of the retinal,
choroidal, and scleral receptors suggests an indirect role for
the acetylcholine system in eye growth. Future work will
target alternate regulatory pathways outside the acetylcholine
system to characterize the mechanism used by muscarinic
antagonists to inhibit myopia development.
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